Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus Katherine A. Lyseng-WilliamsonLesley J. Scott Adis Drug Clinical Q&A 14 July 2013 Pages: 253 - 259
Nanofiltered human C1 inhibitor concentrate (Cinryze®): a guide to its use in hereditary angioedema in the EU Katherine A. Lyseng-Williamson Adis Drug Clinical Q&A 20 July 2013 Pages: 260 - 267
Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling Katherine A. Lyseng-WilliamsonJames E. Frampton Adis Drug Clinical Q&A 20 July 2013 Pages: 268 - 274
Take an individualized, holistic approach when managing epileptic encephalopathies Adis Medical Writers Disease Management 18 June 2013 Pages: 275 - 279
First reports of serious adverse drug reactions in recent weeks Drug Reactions and Interactions 01 August 2013 Pages: 280 - 281
Aminoglycoside use in critically ill patients requires careful regimen planning and drug monitoring to avoid nephrotoxicity Adis Medical Writers Drug Reactions and Interactions 18 June 2013 Pages: 282 - 286
Following the six principles developed by the STAY initiative may improve treatment adherence in patients with schizophrenia Adis Medical Writers Practical Issues and Updates 18 July 2013 Pages: 287 - 290